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Development of an improved vaccine against tuberculosis (TB) is hindered by the lack of a surrogate
of protection. Efﬁcacy of new TB vaccines in humans can only be evaluated by expensive and time
consuming efﬁcacy trials within TB endemic areas. It is critical that vaccines with the greatest potential to
protect are selected for these trials. Mycobacterial growth inhibition assays (MGIAs) have been devel-
oped with the hope that these in-vitro functional assays will correlate with protection, which could aid in
the selection of the best vaccine candidates. The present study describes the use of the BACTEC system to
perform MGIAs in mice. We demonstrate reproducible mycobacterial growth inhibition in splenocytes
from BCG immunised mice compared with unimmunised mice (P < 0.023), which corresponded with in-
vivo efﬁcacy against Mycobacterium tuberculosis (M. tb) challenge. Microarray data showed extensive
differential gene expression in splenocyte responses to ex-vivo BCG stimulation between unimmunised
and BCG-immunised mice. TH1 responses, including IFN-g, nitric oxide synthase (NOS2) and Interleukin
-17 (IL-17) expression were enhanced in BCG immunised mice, indicating a possible mechanism for
mycobacterial growth inhibition. Further investigation into whether the BACTEC MGIA can be used as a
surrogate of protection in humans and preclinical animal models is now warranted.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction that a vaccine is protective.1 If a robust and validated surrogate ofOne of the most challenging aspects of developing an improved
TB vaccine is the demonstration of efﬁcacy to reduce or prevent
disease. At present, the only reliable measures of efﬁcacy are large
scale ﬁeld trials in TB endemic areas; these trials are lengthy,
require thousands of subjects and cost millions of pounds to
perform. Immune correlates expedite the process of evaluating
vaccines for immunogenicity in animal models and early clinical
trials, but do not necessarily imply protection, whereas it has been
suggested that a surrogate of protection could be taken to meanx.ac.uk (L. Marsay),
Rachel.tanner@ndm.ox.ac.uk
), Kristin.grifﬁths@gmail.com
. Stylianou), Phil.marsh@
(A. Williams), Sally.sharpe@
.ox.ac.uk (H. Fletcher),
r Ltd. Open access under CC BY-NC-NDprotection was identiﬁed, it could potentially increase the rate and
accuracy with which we could assess TB vaccine candidates. To
date, no single parameter has been found to robustly correlate with
protection against Mycobacterium tuberculosis (M. tb) in various
preclinical or clinical models.2,3 Even IFN-g, which is known to be
essential for immunity against M. tb and is the primary readout of
many immunological assays assessing vaccine immunogenicity,
does not correlate with protection.4 However, there is a large body
of evidence from gene knockout, cell depletion and adoptive
transfer studies in mice that demonstrate TH1, MHC class-II
restricted CD4þ T cells are essential for protection against M. tb
challenge.5e11 It is currently thought that unbiased approaches
such as transcriptomics could provide us with a panel of bio-
markers which may be predictive of vaccine efﬁcacy. Such studies
have been conducted inmice, looking at gene expressionwithin the
lungs of BCG vaccinated animals, where changes in the connective
tissue structure and function, along with a TH17 cytokine proﬁle
correlated with protection from Mycobacterium bovis challenge.12
Functional assays such as mycobacterial growth inhibition assays
(MGIAs) that measure the summative effect of a range of cellular
mechanisms might prove to be better surrogates of protection. A license.
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sample types obtained from humans and mice.13e16 All MGIAs have
one principle in common; that samples taken after immunisation
should be better able to inhibit growth of mycobacteria in cell
culture, as compared to samples from unimmunised controls.
Cheon et al. have demonstrated the bactericidal activity of whole
blood against M. tb H37Rv in response to BCG immunisation using
the BACTEC system.17 In this report, we demonstrate the enhanced
ability of splenocytes from BCG-immunised mice to inhibit growth
of BCG in-vitro compared to splenocytes from unimmunised mice
using the BACTEC system. We investigated possible mechanisms
behind the mycobacterial growth inhibition by studying gene
expression proﬁles detected using mouse Beadchip arrays. This
analysis revealed greater TH1 responses from BCG-immunisedmice
compared to naïve control animals.
2. Materials and methods
2.1. Animals and immunisations
All mouse experiments were performed using 6e8 week old
female C57bl/6mice (Harlan, UK) andwere approved by the Animal
Use Ethical Committee of Oxford University and fully complied
with all relevant Home Ofﬁce guidelines. BCG Pasteur was used for
all immunisations. Animals were immunised with 1  106 CFU in
100 ml of PBS subcutaneously at the base of the tail and were then
rested for 6 weeks before either sacriﬁce for use in mycobacterial
growth inhibition assays or challenge with M. tb.
2.2. M. tb aerosol challenge
Six weeks after BCG immunisation, mice were aerogenically
challenged withM. tb (Erdman K01 strain; BEI resources, Manassas,
VA) using a Biaera aeroMP nose only challenge apparatus. Bacterial
deposition in the lungs was measured 24 h after challenge and was
found to be w230 CFU/mouse. Mice were sacriﬁced 28 days after
M. tb challenge by cervical dislocation and spleens/lungs were
removed aseptically before being homogenized in PBS using the
Precellys 24 homogenizer (Bertin Technologies). Bacterial loads were
determined by plating 10-fold serial dilutions of tissue homogenates
on Middlebrook 7H10 agar plates supplemented with OADC and
incubated at 37 C. Colonies were counted after 2e3 weeks.
2.3. Splenocyte preparations
Spleens were mashed in PBS and ﬁltered through a 70 mm cell
strainer. Splenocytes were then re-suspended in R10 Media (RPMI
1640 from Sigma Aldrich, 10% FBS, 2 mM L-glutamine; 100U/mL
penicillin,100mg/mLstreptomycin sulphate, all fromInvitrogen) and
counted using a CASY counter (Schärfe Systems, Germany) before
being washed and rested in RPMI without antibiotics for 30 min.
2.4. Mycobacterial preparation for MGIAs
BCG was prepared for use in the MGIA according to methods
previously described.17 Brieﬂy, BCG stocks were propagated in
BACTEC 12B tubes until 2 days after being recorded as positive by
the BACTEC 960 machine (BD Bioscience). Stocks were collected
and frozen at80 C until use. Upon ﬁrst use of a new stock of BCG,
serial 10 fold dilutions were directly inoculated into BACTEC tubes
to produce a standard curve by which the time to positivity (TTP)
could be related to inoculum size. The CFU/ml value of the stock
was also estimated by plating out serial dilutions of the stock onto
7H10 agar plates with OADC supplement and colony counting after
3 weeks incubation at 37 C. The inoculum size required to producea TTP of approximately 6.5 days was determined using a standard
curve of the TTP against inoculum size, this volume was used to
inoculate future BACTEC tubes.
2.5. Determination of mycobacterial growth inhibition
Splenocytes from 8 to 10 mice per group were used to perform
the MGIA. On day 0, duplicate control BACTEC 12B tubes were
directly inoculated with BCG as described above and placed in a
BACTEC 960 instrument until tubes registered as positive. An
identical inoculum was added to duplicate microtubes containing
1 106 splenocytes in RPMI with 10% FCS, L-glutamine and 25 mM
HEPES. BCG infected splenocyte cultures were incubated at 37 C
with gentle rotation for 96 h, after which time the cells were pel-
leted in a microfuge and the supernatant removed. The pellet was
lysed with tissue culture grade water (Sigma Aldrich) to disrupt
mammalian cells. Bacterial pellets were re-suspended in 7H9 me-
dia supplemented with PANTA enrichment media (BD bioscience),
added to BACTEC tubes and incubated with hourly monitoring by
the BACTEC 960 instrument until tubes registered positive. TTP
values were converted into CFU counts using the standard curve of
TTP plotted against inoculum sizewhich could be compared against
the CFU/ml value for each stock of BCG. Finally, the growth ratio
(GR) value for a sample was calculated by the following calculation
GR ¼ CFU Sample (96 h)/CFU day 0 controls.
2.6. RNA extraction, ampliﬁcation and hybridization to microarrays
Splenocytes from 4 naïve and 4 BCG immunised mice, that were
also used to perform the MGIA, were cultured with or without BCG
Pasteurat amultiplicityof infection (MOI)of 1:1 for12h inR10media
without antibiotics. RNAwas extracted from these splenocytes using
the RNeasy kit with DNase digestion (Qiagen). Subsequent RNAwas
analysed for integrity using a Bioanalyzer (Agilent). All RNA samples
had acceptable RNA integrity numbers (RIN) ranging from 7.1 to 8.7.
RNA was ampliﬁed and biotinylated using the TotalPrep kit (Illu-
minaeAmbion). The ampliﬁed RNAwas again assessed for integrity
which revealed average transcript sizes to be between 1000 and
2000bp. Foreach sample, 750ngof ampliﬁedRNAwashybridized (in
a random order to prevent any chip biases) to MouseRef-8 v2.0
beadchips from Illumina according to themanufacturer’s guidelines.
Beadchips were then labelled with streptavidin conjugated Cy3 and
scanned on the same day using an iScan BeadArray reader (Illumina)
tomeasureﬂuorescence signals. Beadstudio v2.0 (Illumina)wasused
to generate gene expression data ﬁles.
2.7. Microarray quality control and ﬁltering of genes
Array quality was assessed using arrayQualityMetrics, a Bio-
conductor package which generates a report of quality metrics.18,19
The quality of all of the arrays was acceptable and they were all
given the same weighting during the analysis.20 Background
correction aided by control probes, followed by quantile normali-
zation, was performed using the Neqc function of the Bioconductor
package limma (linear models for microarray) to normalize ar-
rays.21 Genes that were not signiﬁcantly (p< 0.05) expressed above
the background in any of the arrays were removed from the anal-
ysis, as were genes with an interquartile range of less than 0.3
across the arrays, as this indicated that expression was not altered
in response to stimulation with BCG.
2.8. Identiﬁcation and analysis of differentially expressed genes
Limma was used to identify differentially expressed genes in
response to in-vitro BCG stimulation in unimmunised and BCG
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calculated using a paired analysis between the unstimulated and
BCG stimulated samples for mice in the unimmunised and BCG
immunised groups separately. This was done by ﬁtting a linear
model to account for any systematic or technical factors that might
inﬂuence the expression data. An empirical Bayes method was then
used to moderate standard errors of the estimated log2 fold change
in expression for each gene, the mean log2 fold change in gene
expression (BCG stimulated vs unstimulated) is displayed for each
group of mice. p-values from the resulting comparisons were
adjusted for multiple testing using the BenjaminieHochberg
method with a false discovery rate (FDR) of <0.05. Lists of signiﬁ-
cantly differentially expressed genes were analysed using the open
source Database for Annotation, Visualisation and Integrated Dis-
covery (DAVID) bioinformatics software,22,23 to identify which
pathways from the KEGG database were altered by BCG stimulation
in splenocytes from naïve and BCG vaccinated mice. Genes that
were present in these enriched pathways were used to produce
heatmaps.
The microarray data were submitted to the Gene Expression
Omnibus (GEO) database under accession number GSE42090.
2.9. Statistical analysis
MGIA data were analysed using Prism 5 (GraphPad, software
Inc). Statistical tests to assess the difference between two pop-
ulations were performed using the non-parametric Mann Whitney
T test. Correlations were assessed using SPSS Spearman’s Rho; p-
values and coefﬁcients are reported.
3. Results
3.1. BCG immunisation induces mycobacterial growth inhibition in
mouse splenocytes
Splenocytes obtained from BCG immunised mice were better
able to inhibit growth of BCG in culture than splenocytes taken
from unimmunised animals, with signiﬁcantly reduced log10
transformed GR values (p ¼ 0.023; Figure 1). Log10 GR values
ranged from 0.59 to 0.79 in unimmunised and 0.35e0.73 in BCG
immunised mice, with a difference between the median values of
0.10 log10.Figure 1. BCG immunisation induced mycobacterial growth inhibition in murine
splenocytes. Data shown are log10 transformed GR values for unimmunised and BCG
immunised (1  106 CFU s.c) C57bl/6 mice, n ¼ 8/group. Bars represent the median
values. TTP values were converted to CFU values, GR ¼ CFU day 4 sample tubes/CFU
day 0 control tubes.3.2. Mycobacterial growth inhibition corresponds with protection
from M. tb challenge
In order to demonstrate that BCG-inducedmycobacterial growth
inhibition detected in the MGIA corresponded with protection
against M. tb challenge in vivo, BCG immunised and unimmunised
mice were divided into two groups, one of which was used to
perform the MGIA and the remaining group was challenged with
aerosolized M. tb. The same mice could not be used for both the
MGIA and the M. tb challenge due to the use of splenocytes to
perform the MGIA. MGIA data for these animals are displayed in
Figure 2A, demonstrating that the BCG-induced mycobacterial
growth inhibition detected in the previous experiment was repro-
ducible. Log10 GR values ranged from 0.55 to 0.9 in unimmunised
and 0.37e0.61 in BCG immunised mice, with a difference between
the median values of 0.17 log10. The BCG immunisation route, dose
and interval that induced mycobacterial growth inhibition in vitro,
conferredprotection againstM. tb challenge in the lungs and spleens
of M. tb challenged animals as shown in Figure 2B and C, respec-
tively. BCG immunisedmice had signiﬁcantly lower levels ofM. tb in
the lungs (p ¼ 0.0002) and spleen (p ¼ 0.0003) compared with
unimmunised animals 28 days following M. tb challenge. The level
of protection affordedwas a 0.76 log10 and 0.6 log10 reduction in the
median CFU/organ counts in the lungs and spleens, respectively.
3.3. Differential gene expression in splenocytes from naïve and BCG
immunised mice
In order to gain insight into the mechanisms underlying the
mycobacterial growth inhibition detected in-vitro, whole-genome
differential gene expression (DGE) studies were performed on a sub-
set of splenocytes from the same mice (4 unimmunised and 4 BCG
immunised) used to perform the MGIA in the second experiment
described above. Illumina MouseRef-8 v2.0 beadchip microarrays
were used to assess DGE responses in splenocytes fromunimmunised
and BCG immunised mice when stimulated with BCG in-vitro and
compared with experimentally matched un-stimulated samples. Out
of approximately 19,100 individual genes represented on the arrays,
2438 were differentially expressed at a false discovery rate (FDR) of
<0.05. Of these genes, 1150 were differentially expressed in both
unimmunised and BCG immunised mouse splenocytes; the 20 most
signiﬁcant genes in this list are displayed inTable 1. A number of these
genes were signiﬁcantly differentially expressed between unim-
munised and BCG immunised mice in response to in-vitro BCG stim-
ulation (naïve stimulated vs. BCG immunised stimulated)
(Supplementary Table 1). The list of common genes contained a
number of inﬂammatory markers that are known to be important in
mycobacterial immunity including IFN-g, TNF-a, CXCL9 and CSF2 (the
gene that encodes for GM-CSF). The ﬁnding that these crucial TH1
genes were differentially expressed in splenocytes from both unim-
munised and BCG immunised mice suggests a substantial level of
innate immunity against mycobacteria. However, immunisation with
BCG appeared to enhance the levels of gene expression of these
important inﬂammatorygenes, as seenby the relative Log2 fold change
values. There were 1153 genes that were speciﬁcally differentially
expressed in BCG immunised mouse splenocytes; the top 10 genes
from this list are displayed in Table 2. Most notably, IFN-g inducible
nitric oxide synthase (NOS2) was only found to be signiﬁcantly
differentially expressed in BCG immunisedmice alone, indicating that
high levels of IFN-g are required for the induction of this gene.
3.4. Identifying biological pathways altered by BCG stimulation
All genes identiﬁed as being differentially expressed in BCG
immunised mice were used to identify biological pathways altered
Figure 2. Mycobacterial growth inhibition is associated with protection from M. tb challenge in-vivo. Groups of 10 BCG immunised or unimmunised mice were either aerogenically
challenged withM. tb Erdman or were sacriﬁced for use in an MGIA. (A) Log10 GR values are displayed for both BCG immunised and unimmunised animals. (B) CFU/organ data from
lungs and (C) CFU/organ data from spleens of M. tb challenged animals. Bars represent the median values.
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grouped together to produce functional annotation charts from the
Kyoto encyclopaedia of genes and genomes (KEGG) database. This
gene-set was enriched for in the cytokineecytokine receptor
interaction (Adj. P value ¼ 3.9E-6, 61 genes, 3.4%), Lysosome (Adj. P
value ¼ 1.3E-4, 34 genes, 1.9%) and toll like receptor (Adj. P
value ¼ 1.2E-4, 30 genes, 1.7%) pathways. The genes identiﬁed asTable 1
Top 20 differentially expressed genes common to naïve and BCG immunised mice.
Gene
symbol
Log2FC naive Adj. p-value
naive
Log2FC BCG Adj. p-value
BCG
Ifng 5.4833404 1.23E-11 7.9826583 7.53E-16
Ifng 4.352348 1.73E-10 6.9204075 2.18E-15
Serpina3f 5.742117 1.31E-12 6.3095588 2.18E-15
Cxcl9 5.1519307 5.40E-12 5.8514297 1.25E-14
Cxcl1 5.3922714 1.04E-10 4.9087237 2.57E-11
Il1a 4.5625431 1.31E-12 4.8744532 1.94E-14
Edn1 3.9405469 1.03E-11 4.549759 3.37E-14
Csf2 2.702213 2.44E-09 4.318917 2.12E-13
Tnf 3.8755611 5.89E-11 4.2363571 4.19E-13
Il1b 4.2602312 1.91E-12 4.1296659 7.00E-14
Il1rn 3.3316204 2.13E-10 3.9818977 1.43E-12
Ccl3 3.2805672 7.00E-11 3.59441 2.76E-12
Gbp2 3.4827162 2.99E-12 3.5658031 2.18E-12
AA467197 2.6059186 3.91E-10 3.4287748 8.15E-13
Lyz 2.564697 3.31E-11 2.822468 4.92E-12
Igf1 2.813544 2.86E-10 3.10288 4.01E-11
Lyzs 3.146398 9.94E-11 3.400583 2.11E-12
Lyz2 3.168909 1.23E-11 3.510704 3.29E-13
Ltf 3.202541 2.17E-10 3.595911 6.12E-12
Retnlg 4.796292 1.31E-12 4.902506 1.29E-14
The table contains genes that were differentially expressed in splenocytes stimu-
lated with BCG in both the BCG immunised and unimmunised mice (unstimulated
vs. stimulated). The log2FC column indicates the fold change in differential
expression of a gene. Repeated gene symbols indicate separate probes for a single
gene and negative FC values indicate down regulation of a gene. n ¼ 4 mice in each
group.belonging to these altered biological pathways provided concise
lists that were then used to generate heatmaps which are displayed
in Figure 3. The heatmaps show the fold change in expression of
individual genes by colour for each BCG immunised mouse in
response to in-vitro BCG stimulation (stimulated vs. unstimulated).
The cytokineecytokine receptor interaction pathway is very
extensive and contains many inﬂammatory mediators that were
found to be up-regulated in response to BCG stimulation including
IFN-g, TNF-a, IL-17, FASL and CCR5 (Figure 3A). The TLR signalling
pathway contained TLR-6, Myd88 and NFkb which are involved in
transcription of inﬂammatory mediators such as TNF-a and co-
stimulatory molecules including CD40 and CD80 (Figure 3B). The
vast majority of differentially expressed genes within the lysosome
pathway were found to be down-regulated, including a number of
cathepsins and vacuolar ATPase components (Figure 3C).Table 2
Top 10 most signiﬁcant differentially expressed genes in splenocytes from BCG
immunised mice only.
Gene symbol Log2FC Adj. p-value
Nos2 1.684895 7.00E-06
Zbtb32 1.430728 1.30E-05
Gpr31c 1.2674041 1.20E-05
Timp1 1.1180031 4.00E-06
Timp1 1.01354 4.20E-05
Rbpj 0.9345954 3.40E-05
Etv6 0.9270242 4.10E-05
4732429D16Rik 0.690589 3.70E-05
Ccl9 0.854685 2.80E-05
Cryl1 0.905844 3.20E-05
The table contains genes that were speciﬁcally differentially expressed in spleno-
cytes taken from BCG immunised mice only, in response to in-vitro BCG stimulation
(BCG immunised unstimulated vs. BCG immunised stimulated). The log2FC column
indicates the fold change level of differential expression of a gene. Repeated gene
symbols indicate separate probes for a single gene and negative FC values indicate
down regulation of a gene, n ¼ 4.
Figure 3. Differential expression of genes involved in biological pathways altered by
stimulation with BCG in BCG immunised mice. (A) Genes present in the cytokinee
cytokine receptor pathway. (B) Genes present in the Toll like receptor pathway. (C)
Genes present in the Lysosome pathway. Each column indicates the levels of differ-
ential expression for each BCG immunised mouse with dark red indicating a greater
than 5 fold increase in expression (stimulated vs. unstimulated) and dark blue indi-
cating a greater than 5 fold decrease in expression (stimulated vs. unstimulated), n ¼ 4.
Table 3
Correlations between gene expression and mycobacterial Log10 GR values.
Gene symbol Correlation coefﬁcient Signiﬁcance (2-tailed)
Atp6v0a1 0.810 0.015
Il15ra 0.786 0.021
Cxcl1 0.762 0.028
Cxcl9 0.810 0.028
Psap 0.762 0.028
Ifng 0.738 0.037
Manba 0.738 0.037
CD70 0.714 0.047
Ikbkg 0.714 0.047
Gene expression values from naïve and BCG immunised mouse splenocytes in
response to in-vitro BCG stimulation (BCG stimulated) were correlated against
mycobacterial growth inhibition values (Log10 GR) for the same mice using Spear-
man’s rho. The gene list used for the correlations was the same as was used to
produce the heatmaps in Figure 3. n ¼ 8 (4 naïve and 4 BCG immunised mice).
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The splenocytes used to perform DGE andmycobacterial growth
inhibition studies were taken from the same animals; therefore, it
was possible to directly correlate BCG stimulated gene expressionlevels with mycobacterial growth levels in these animals. The in-
vitro stimulation with BCG mimicked the BCG infection in the
MGIA. The list of genes selected for the heatmaps in Figure 3 were
used to perform correlations against the Log10 GR values
(Figure 2A) from 4 naïve and 4 BCG immunised mice whose
Log10 GR values ranged from 0.55 to 0.90 and 0.51e0.61, respec-
tively. Out of a possible 115 genes present in the list, 9 genes
signiﬁcantly correlated with mycobacterial GR values (Table 3).4. Discussion
In this study, we found that BCG immunisation in mice led to an
enhanced ability of splenocytes to inhibit the growth of BCG in
culture which corresponded with protection from M. tb challenge
in experimentally matched animals. The difference in mycobacte-
rial growth between naïve and BCG immunised animals was less
than 0.2 log10, although this difference may be improved following
further optimisation. Extending the duration of the BACTEC MGIA
to 7 days may result in greater levels of growth inhibition. The use
of pathogenic M. tb in the assay could potentially accentuate dif-
ferences in growth inhibition between immunised and unim-
munised animals, although this wouldmake the assay less practical
in terms of the increased level of biological containment facilities
that would be needed. Our study suggests that the BACTEC MGIA
may be a useful alternative to aerosol challenge with virulentM. tb
to assess the performance of TB vaccine candidates in mice. If in-
vitro mycobacterial growth inhibition is found to correlate with
protection in-vivo, then such an assay would enable more rapid
screening of a large number of candidates, allowing down-selection
for more advanced pre-clinical and clinical testing. In similar mu-
rine studies by Kolibab et al., BCG immunisation resulted in growth
inhibition in BCG infected bone marrow macrophages co-cultured
with splenocytes. In that system, the level of mycobacterial
growth inhibition was found to be around 1 Log10 after a culture
period of 7 days. Furthermore, Kolibab et al. showed that in-vitro
mycobacterial growth inhibition following vaccination correlated
with the level of protection afforded by those vaccines.14,24 The
assay described in this present study does not require the har-
vesting and infection of macrophages and therefore requires less
manipulation and fewer animals/cells than other MGIAs14e16,24,25
which makes the assay simple and relatively quick to perform.
MGIAs measure the summed ability of immune cells to control
mycobacterial growth; we therefore reasoned that microarrays
would be a suitable platform to investigate the multiple immune
pathways that are likely to be contributing to the control of
mycobacterial growth in this system. We found a number of genes
known to be important in immunity againstM. tb, including IFN-g,
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splenocytes from both naïve and BCG immunisedmice, but more so
in BCG immunised mice. This indicates that BCG immunised ani-
mals could produce a more robust TH1 type response to mycobac-
terial stimulation during the MGIA compared to naïve control
animals. A large number of genes were speciﬁcally differentially
expressed in BCG immunised mice, indicating a broadening of the
immune response in these animals. Our ﬁndings from this micro-
array study of in-vitro responses to BCG stimulation are similar to
those found in other microarray studies of ex-vivo responses to
mycobacterial challenge in mice. IFN-g and genes modulated by
IFN-g including CXCL9 and CXCL10 have been found to be up-
regulated to a greater extent in the lungs of BCG immunised mice
in response to M. tb challenge as compared to naïve mice.26
Increased expression of IL-17 in BCG immunised animals has
been suggested to contribute towards protective immunity in
mice12 as well as cattle.27
Fletcher et al., unpublished data, have examined gene expres-
sion in 10 week old South African infants immunised with BCG at
birth. Similar to the design in this mouse study, gene signatures
were obtained from peripheral blood mononuclear cells (PBMCs)
stimulated in-vitro with BCG or media only for 12 h. There was
overlap between the gene signatures identiﬁed in mice and these
infants, with up-regulation of IFN-g modulated genes and down-
regulation of genes in the lysosome pathway in response to in-vi-
tro BCG stimulation. However, whereas all of the mice (both
unimmunised and BCG immunised) showed increased expression
of IFN-g, many of the infants (despite all infants receiving BCG at
birth) did not have increased IFN-g in response to in-vitro stimu-
lation with BCG. This may be due to immaturity of the infant im-
mune system, or it may reﬂect increased resistance of mice to
mycobacterial infection due to innate immune responses.
A biological pathways analysis identiﬁed the cytokineecytokine
receptor pathway as having many genes involved in the response to
BCG stimulation in BCG immunised mice. As mentioned above, the
lysosome pathway was also identiﬁed as containing a signiﬁcant
number of differentially expressed genes in BCG immunised mice.
Surprisingly, the majority of lysosome related genes were down-
regulated. Activation of the lysosome pathway to produce mature
phagolysosomes is considered to be a fundamental mechanism for
the destruction of mycobacteria withinmacrophages; therefore, we
expectedmarkers of phagolysosomematuration including vacuolar
ATPases, anti-microbial proteins and peptides to be up-regulated in
immunised mice. One explanation for the observed down-
regulation could be that the high level of BCG used for the stimu-
lation actively inhibited the lysosome pathway via ManLAM. BCG,
like M. tb, expresses ManLAM28 which has been shown to disrupt
phagolysosome maturation.29 Had a lower dose of BCG been used
for the stimulation, down-regulation of the lysosome pathwaymay
not have been observed. It is also possible that the effect is due to
cytokine mediated apoptosis of neutrophils, macrophages and NKT
cells during culture with BCG and thus the relative abundance of
transcripts was reduced in these samples compared to unstimu-
lated controls. Enhanced expression of IFN-g, TNF-a and NOS2 in
the BCG immunised animals may also account for the lower levels
of expression of lysosome related genes in these samples compared
to the naïve animals. In the murine model of Trypanosoma cruzi
infection, IFN-g has been shown to modulate Fas/FasL expression
and subsequent NO-induced apoptosis of splenocytes during the
acute phase of infection.30 Furthermore, recent work by Herbst and
colleagues suggests that NO-induced apoptosis of M. tb infected
macrophages is an important defence mechanism in mice.31
Further investigation into the activation or repression of biolog-
ical pathways throughout the time course of the MGIA and with
varying levels of BCG stimulation, would help to determine themechanisms involved in mycobacterial growth inhibition during
the MGIA.
When correlations were performed between gene expression
and mycobacterial growth inhibition (Log10 GR) for naïve and BCG
immunised mice, the genes found to correlate could largely be
divided into two groups: proinﬂammatory genes and genes asso-
ciatedwith the lysosome pathway. Genes that negatively correlated
with mycobacterial growth included the proinﬂammatory genes
IFN-g, IL-15Ra, CXCL9, CD70 and Ikbkg, whereas genes that posi-
tively correlated with mycobacterial growth included the lysosome
pathway genes Atp6v0a1 and Manba.
In conclusion, our study has shown that splenocytes from BCG
immunised mice are able to inhibit mycobacterial growth in-vitro
as measured by the BACTEC MGIA and that growth inhibition was
associated with protection from challenge with M. tb in experi-
mentally matched animals. The array data in this present study
indicate that mycobacterial growth inhibition was associated with
increased expression of TH1 inﬂammatory markers and that
expression of genes in the lysosome pathway was associated with
lack of control of mycobacterial growth. This assay requires mini-
mal manipulation, utilises the rapid and automated BACTEC system
to quantify mycobacteria and requires low numbers of host cells. It
is therefore, a useful tool for the screening of candidate TB vaccines
and for exploring the immune processes underlying the control of
mycobacterial replication in-vitro and in-vivo.
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